Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction

Purpose To identify the key formulation factors controlling the initial drug and polymer dissolution rates from an amorphous solid dispersion (ASD). Methods Ketoconazole (KTZ) ASDs using PVP, PVP-VA, HMPC, or HPMC-AS as polymeric matrix were prepared. For each drug-polymer system, two types of formu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical research 2016-10, Vol.33 (10), p.2445-2458
Hauptverfasser: Chen, Yuejie, Wang, Shujing, Wang, Shan, Liu, Chengyu, Su, Ching, Hageman, Michael, Hussain, Munir, Haskell, Roy, Stefanski, Kevin, Qian, Feng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2458
container_issue 10
container_start_page 2445
container_title Pharmaceutical research
container_volume 33
creator Chen, Yuejie
Wang, Shujing
Wang, Shan
Liu, Chengyu
Su, Ching
Hageman, Michael
Hussain, Munir
Haskell, Roy
Stefanski, Kevin
Qian, Feng
description Purpose To identify the key formulation factors controlling the initial drug and polymer dissolution rates from an amorphous solid dispersion (ASD). Methods Ketoconazole (KTZ) ASDs using PVP, PVP-VA, HMPC, or HPMC-AS as polymeric matrix were prepared. For each drug-polymer system, two types of formulations with the same composition were prepared: 1. Spray dried dispersion (SDD) that is homogenous at molecular level, 2. Physical blend of SDD (80% drug loading) and pure polymer (SDD-PB) that is homogenous only at powder level. Flory-Huggins interaction parameters (χ) between KTZ and the four polymers were obtained by Flory-Huggins model fitting. Solution 13 C NMR and FT-IR were conducted to investigate the specific drug-polymer interaction in the solution and solid state, respectively. Intrinsic dissolution of both the drug and the polymer from ASDs were studied using a Higuchi style intrinsic dissolution apparatus. PXRD and confocal Raman microscopy were used to confirm the absence of drug crystallinity on the tablet surface before and after dissolution study. Results In solid state, KTZ is completely miscible with PVP, PVP-VA, or HPMC-AS, demonstrated by the negative χ values of −0.36, −0.46, −1.68, respectively; while is poorly miscible with HPMC shown by a positive χ value of 0.23. According to solution 13 C NMR and FT-IR studies, KTZ interacts with HPMC-AS strongly through H-bonding and dipole induced interaction; with PVPs and PVP-VA moderately through dipole-induced interactions; and with HPMC weakly without detectable attractive interaction. Furthermore, the “apparent” strength of drug-polymer interaction, measured by the extent of peak shift on NMR or FT-IR spectra, increases with the increasing number of interacting drug-polymer pairs. For ASDs with the presence of considerable drug-polymer interactions, such as KTZ/PVPs, KTZ/PVP-VA, or KTZ /HPMC-AS systems, drug released at the same rate as the polymer when intimate drug-polymer mixing was ensured (i.e., the SDD systems); while drug released much slower than the polymer when molecular level mixing or drug-polymer interaction was absent (SDD-PB systems). For ASDs without drug-polymer interaction (i.e., KTZ/HPMC systems), the mixing homogeneity had little impact on the release rate of either the drug or the polymer thus SDD and SDD-PB demonstrated the same drug or polymer release rate, while the drug released slowly and independently of polymer release. Conclusions The initial drug release from an A
doi_str_mv 10.1007/s11095-016-1969-2
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1815975064</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A724212692</galeid><sourcerecordid>A724212692</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-5c746fc191f80527c9b6c15f3d7f7980c5e578a82925f4d1e1322585b9d287d03</originalsourceid><addsrcrecordid>eNp1kUuLFDEUhYMoTjv6A9xIgRs3GXNTlUqybHp8NAwoqOAuVOfRZkglbVIF9r83NT0jM6JkEcj5zuHeHIReArkAQvjbAkAkwwR6DLKXmD5CK2C8xZJ03x-jFeG0w4J3cIaelXJNCBEgu6fojHIqWtGSFfq1jX7yQ2gu87xvLn0pKcyTT7FxOY3Nekz58CPNpfmSgjcLcLC5VL00mxSnnEKwptkdm88pHEebH0QM0dzk4jtxGyebB72Iz9ETN4RiX9ze5-jb-3dfNx_x1acP2836CmtG2ISZ5l3vNEhwgjDKtdz1GphrDXdcCqKZZVwMgkrKXGfAQkspE2wnDRXckPYcvTnlHnL6OdsyqdEXbUMYoq17KRDAJGek7yr6-i_0Os051uluqBZId5_aD8EqH12a6kpLqFrX_6ZAe0krdfEPqh5jR69TtM7X9wcGOBl0TqVk69Qh-3HIRwVELW2rU9uqtq2WttXieXU78LwbrfnjuKu3AvQElCrFvc33Nvpv6m8-urPA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1815310464</pqid></control><display><type>article</type><title>Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Chen, Yuejie ; Wang, Shujing ; Wang, Shan ; Liu, Chengyu ; Su, Ching ; Hageman, Michael ; Hussain, Munir ; Haskell, Roy ; Stefanski, Kevin ; Qian, Feng</creator><creatorcontrib>Chen, Yuejie ; Wang, Shujing ; Wang, Shan ; Liu, Chengyu ; Su, Ching ; Hageman, Michael ; Hussain, Munir ; Haskell, Roy ; Stefanski, Kevin ; Qian, Feng</creatorcontrib><description>Purpose To identify the key formulation factors controlling the initial drug and polymer dissolution rates from an amorphous solid dispersion (ASD). Methods Ketoconazole (KTZ) ASDs using PVP, PVP-VA, HMPC, or HPMC-AS as polymeric matrix were prepared. For each drug-polymer system, two types of formulations with the same composition were prepared: 1. Spray dried dispersion (SDD) that is homogenous at molecular level, 2. Physical blend of SDD (80% drug loading) and pure polymer (SDD-PB) that is homogenous only at powder level. Flory-Huggins interaction parameters (χ) between KTZ and the four polymers were obtained by Flory-Huggins model fitting. Solution 13 C NMR and FT-IR were conducted to investigate the specific drug-polymer interaction in the solution and solid state, respectively. Intrinsic dissolution of both the drug and the polymer from ASDs were studied using a Higuchi style intrinsic dissolution apparatus. PXRD and confocal Raman microscopy were used to confirm the absence of drug crystallinity on the tablet surface before and after dissolution study. Results In solid state, KTZ is completely miscible with PVP, PVP-VA, or HPMC-AS, demonstrated by the negative χ values of −0.36, −0.46, −1.68, respectively; while is poorly miscible with HPMC shown by a positive χ value of 0.23. According to solution 13 C NMR and FT-IR studies, KTZ interacts with HPMC-AS strongly through H-bonding and dipole induced interaction; with PVPs and PVP-VA moderately through dipole-induced interactions; and with HPMC weakly without detectable attractive interaction. Furthermore, the “apparent” strength of drug-polymer interaction, measured by the extent of peak shift on NMR or FT-IR spectra, increases with the increasing number of interacting drug-polymer pairs. For ASDs with the presence of considerable drug-polymer interactions, such as KTZ/PVPs, KTZ/PVP-VA, or KTZ /HPMC-AS systems, drug released at the same rate as the polymer when intimate drug-polymer mixing was ensured (i.e., the SDD systems); while drug released much slower than the polymer when molecular level mixing or drug-polymer interaction was absent (SDD-PB systems). For ASDs without drug-polymer interaction (i.e., KTZ/HPMC systems), the mixing homogeneity had little impact on the release rate of either the drug or the polymer thus SDD and SDD-PB demonstrated the same drug or polymer release rate, while the drug released slowly and independently of polymer release. Conclusions The initial drug release from an ASD was controlled by 1) the polymer release rate; 2) the strength of drug-polymer interaction, including the intrinsic interaction caused by the chemistry of the drug and the polymer (measured by the χ value), as well as that the apparent interaction caused by the drug-polymer ratio (measure by the extent of peak shift on spectroscopic analysis); and 3) the level of mixing homogeneity between the drug and polymer. In summary, the selection of polymer, drug-polymer ratio, and ASD processing conditions have profound impacts on the dissolution behavior of ASDs. Graphical Abstract Relationship between initial drug and polymer dissolution rates from amorphous solid dispersions with different mixing uniformity and drug-polymer interactions</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-016-1969-2</identifier><identifier>PMID: 27283830</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biochemistry ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Drug interactions ; Drug Interactions - physiology ; Drug Liberation - physiology ; Drugs ; Medical Law ; Pharmaceutical Preparations - chemistry ; Pharmaceutical Preparations - metabolism ; Pharmaceuticals ; Pharmacology/Toxicology ; Pharmacy ; Polymer industry ; Polymers ; Polymers - chemistry ; Polymers - metabolism ; Research Paper ; Solubility ; X-Ray Diffraction - methods</subject><ispartof>Pharmaceutical research, 2016-10, Vol.33 (10), p.2445-2458</ispartof><rights>Springer Science+Business Media New York 2016</rights><rights>COPYRIGHT 2016 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-5c746fc191f80527c9b6c15f3d7f7980c5e578a82925f4d1e1322585b9d287d03</citedby><cites>FETCH-LOGICAL-c505t-5c746fc191f80527c9b6c15f3d7f7980c5e578a82925f4d1e1322585b9d287d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11095-016-1969-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11095-016-1969-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27283830$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Yuejie</creatorcontrib><creatorcontrib>Wang, Shujing</creatorcontrib><creatorcontrib>Wang, Shan</creatorcontrib><creatorcontrib>Liu, Chengyu</creatorcontrib><creatorcontrib>Su, Ching</creatorcontrib><creatorcontrib>Hageman, Michael</creatorcontrib><creatorcontrib>Hussain, Munir</creatorcontrib><creatorcontrib>Haskell, Roy</creatorcontrib><creatorcontrib>Stefanski, Kevin</creatorcontrib><creatorcontrib>Qian, Feng</creatorcontrib><title>Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><addtitle>Pharm Res</addtitle><description>Purpose To identify the key formulation factors controlling the initial drug and polymer dissolution rates from an amorphous solid dispersion (ASD). Methods Ketoconazole (KTZ) ASDs using PVP, PVP-VA, HMPC, or HPMC-AS as polymeric matrix were prepared. For each drug-polymer system, two types of formulations with the same composition were prepared: 1. Spray dried dispersion (SDD) that is homogenous at molecular level, 2. Physical blend of SDD (80% drug loading) and pure polymer (SDD-PB) that is homogenous only at powder level. Flory-Huggins interaction parameters (χ) between KTZ and the four polymers were obtained by Flory-Huggins model fitting. Solution 13 C NMR and FT-IR were conducted to investigate the specific drug-polymer interaction in the solution and solid state, respectively. Intrinsic dissolution of both the drug and the polymer from ASDs were studied using a Higuchi style intrinsic dissolution apparatus. PXRD and confocal Raman microscopy were used to confirm the absence of drug crystallinity on the tablet surface before and after dissolution study. Results In solid state, KTZ is completely miscible with PVP, PVP-VA, or HPMC-AS, demonstrated by the negative χ values of −0.36, −0.46, −1.68, respectively; while is poorly miscible with HPMC shown by a positive χ value of 0.23. According to solution 13 C NMR and FT-IR studies, KTZ interacts with HPMC-AS strongly through H-bonding and dipole induced interaction; with PVPs and PVP-VA moderately through dipole-induced interactions; and with HPMC weakly without detectable attractive interaction. Furthermore, the “apparent” strength of drug-polymer interaction, measured by the extent of peak shift on NMR or FT-IR spectra, increases with the increasing number of interacting drug-polymer pairs. For ASDs with the presence of considerable drug-polymer interactions, such as KTZ/PVPs, KTZ/PVP-VA, or KTZ /HPMC-AS systems, drug released at the same rate as the polymer when intimate drug-polymer mixing was ensured (i.e., the SDD systems); while drug released much slower than the polymer when molecular level mixing or drug-polymer interaction was absent (SDD-PB systems). For ASDs without drug-polymer interaction (i.e., KTZ/HPMC systems), the mixing homogeneity had little impact on the release rate of either the drug or the polymer thus SDD and SDD-PB demonstrated the same drug or polymer release rate, while the drug released slowly and independently of polymer release. Conclusions The initial drug release from an ASD was controlled by 1) the polymer release rate; 2) the strength of drug-polymer interaction, including the intrinsic interaction caused by the chemistry of the drug and the polymer (measured by the χ value), as well as that the apparent interaction caused by the drug-polymer ratio (measure by the extent of peak shift on spectroscopic analysis); and 3) the level of mixing homogeneity between the drug and polymer. In summary, the selection of polymer, drug-polymer ratio, and ASD processing conditions have profound impacts on the dissolution behavior of ASDs. Graphical Abstract Relationship between initial drug and polymer dissolution rates from amorphous solid dispersions with different mixing uniformity and drug-polymer interactions</description><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Biomedicine</subject><subject>Drug interactions</subject><subject>Drug Interactions - physiology</subject><subject>Drug Liberation - physiology</subject><subject>Drugs</subject><subject>Medical Law</subject><subject>Pharmaceutical Preparations - chemistry</subject><subject>Pharmaceutical Preparations - metabolism</subject><subject>Pharmaceuticals</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Polymer industry</subject><subject>Polymers</subject><subject>Polymers - chemistry</subject><subject>Polymers - metabolism</subject><subject>Research Paper</subject><subject>Solubility</subject><subject>X-Ray Diffraction - methods</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUuLFDEUhYMoTjv6A9xIgRs3GXNTlUqybHp8NAwoqOAuVOfRZkglbVIF9r83NT0jM6JkEcj5zuHeHIReArkAQvjbAkAkwwR6DLKXmD5CK2C8xZJ03x-jFeG0w4J3cIaelXJNCBEgu6fojHIqWtGSFfq1jX7yQ2gu87xvLn0pKcyTT7FxOY3Nekz58CPNpfmSgjcLcLC5VL00mxSnnEKwptkdm88pHEebH0QM0dzk4jtxGyebB72Iz9ETN4RiX9ze5-jb-3dfNx_x1acP2836CmtG2ISZ5l3vNEhwgjDKtdz1GphrDXdcCqKZZVwMgkrKXGfAQkspE2wnDRXckPYcvTnlHnL6OdsyqdEXbUMYoq17KRDAJGek7yr6-i_0Os051uluqBZId5_aD8EqH12a6kpLqFrX_6ZAe0krdfEPqh5jR69TtM7X9wcGOBl0TqVk69Qh-3HIRwVELW2rU9uqtq2WttXieXU78LwbrfnjuKu3AvQElCrFvc33Nvpv6m8-urPA</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Chen, Yuejie</creator><creator>Wang, Shujing</creator><creator>Wang, Shan</creator><creator>Liu, Chengyu</creator><creator>Su, Ching</creator><creator>Hageman, Michael</creator><creator>Hussain, Munir</creator><creator>Haskell, Roy</creator><creator>Stefanski, Kevin</creator><creator>Qian, Feng</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20161001</creationdate><title>Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction</title><author>Chen, Yuejie ; Wang, Shujing ; Wang, Shan ; Liu, Chengyu ; Su, Ching ; Hageman, Michael ; Hussain, Munir ; Haskell, Roy ; Stefanski, Kevin ; Qian, Feng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-5c746fc191f80527c9b6c15f3d7f7980c5e578a82925f4d1e1322585b9d287d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Biomedicine</topic><topic>Drug interactions</topic><topic>Drug Interactions - physiology</topic><topic>Drug Liberation - physiology</topic><topic>Drugs</topic><topic>Medical Law</topic><topic>Pharmaceutical Preparations - chemistry</topic><topic>Pharmaceutical Preparations - metabolism</topic><topic>Pharmaceuticals</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Polymer industry</topic><topic>Polymers</topic><topic>Polymers - chemistry</topic><topic>Polymers - metabolism</topic><topic>Research Paper</topic><topic>Solubility</topic><topic>X-Ray Diffraction - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Yuejie</creatorcontrib><creatorcontrib>Wang, Shujing</creatorcontrib><creatorcontrib>Wang, Shan</creatorcontrib><creatorcontrib>Liu, Chengyu</creatorcontrib><creatorcontrib>Su, Ching</creatorcontrib><creatorcontrib>Hageman, Michael</creatorcontrib><creatorcontrib>Hussain, Munir</creatorcontrib><creatorcontrib>Haskell, Roy</creatorcontrib><creatorcontrib>Stefanski, Kevin</creatorcontrib><creatorcontrib>Qian, Feng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Yuejie</au><au>Wang, Shujing</au><au>Wang, Shan</au><au>Liu, Chengyu</au><au>Su, Ching</au><au>Hageman, Michael</au><au>Hussain, Munir</au><au>Haskell, Roy</au><au>Stefanski, Kevin</au><au>Qian, Feng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction</atitle><jtitle>Pharmaceutical research</jtitle><stitle>Pharm Res</stitle><addtitle>Pharm Res</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>33</volume><issue>10</issue><spage>2445</spage><epage>2458</epage><pages>2445-2458</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><abstract>Purpose To identify the key formulation factors controlling the initial drug and polymer dissolution rates from an amorphous solid dispersion (ASD). Methods Ketoconazole (KTZ) ASDs using PVP, PVP-VA, HMPC, or HPMC-AS as polymeric matrix were prepared. For each drug-polymer system, two types of formulations with the same composition were prepared: 1. Spray dried dispersion (SDD) that is homogenous at molecular level, 2. Physical blend of SDD (80% drug loading) and pure polymer (SDD-PB) that is homogenous only at powder level. Flory-Huggins interaction parameters (χ) between KTZ and the four polymers were obtained by Flory-Huggins model fitting. Solution 13 C NMR and FT-IR were conducted to investigate the specific drug-polymer interaction in the solution and solid state, respectively. Intrinsic dissolution of both the drug and the polymer from ASDs were studied using a Higuchi style intrinsic dissolution apparatus. PXRD and confocal Raman microscopy were used to confirm the absence of drug crystallinity on the tablet surface before and after dissolution study. Results In solid state, KTZ is completely miscible with PVP, PVP-VA, or HPMC-AS, demonstrated by the negative χ values of −0.36, −0.46, −1.68, respectively; while is poorly miscible with HPMC shown by a positive χ value of 0.23. According to solution 13 C NMR and FT-IR studies, KTZ interacts with HPMC-AS strongly through H-bonding and dipole induced interaction; with PVPs and PVP-VA moderately through dipole-induced interactions; and with HPMC weakly without detectable attractive interaction. Furthermore, the “apparent” strength of drug-polymer interaction, measured by the extent of peak shift on NMR or FT-IR spectra, increases with the increasing number of interacting drug-polymer pairs. For ASDs with the presence of considerable drug-polymer interactions, such as KTZ/PVPs, KTZ/PVP-VA, or KTZ /HPMC-AS systems, drug released at the same rate as the polymer when intimate drug-polymer mixing was ensured (i.e., the SDD systems); while drug released much slower than the polymer when molecular level mixing or drug-polymer interaction was absent (SDD-PB systems). For ASDs without drug-polymer interaction (i.e., KTZ/HPMC systems), the mixing homogeneity had little impact on the release rate of either the drug or the polymer thus SDD and SDD-PB demonstrated the same drug or polymer release rate, while the drug released slowly and independently of polymer release. Conclusions The initial drug release from an ASD was controlled by 1) the polymer release rate; 2) the strength of drug-polymer interaction, including the intrinsic interaction caused by the chemistry of the drug and the polymer (measured by the χ value), as well as that the apparent interaction caused by the drug-polymer ratio (measure by the extent of peak shift on spectroscopic analysis); and 3) the level of mixing homogeneity between the drug and polymer. In summary, the selection of polymer, drug-polymer ratio, and ASD processing conditions have profound impacts on the dissolution behavior of ASDs. Graphical Abstract Relationship between initial drug and polymer dissolution rates from amorphous solid dispersions with different mixing uniformity and drug-polymer interactions</abstract><cop>New York</cop><pub>Springer US</pub><pmid>27283830</pmid><doi>10.1007/s11095-016-1969-2</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0724-8741
ispartof Pharmaceutical research, 2016-10, Vol.33 (10), p.2445-2458
issn 0724-8741
1573-904X
language eng
recordid cdi_proquest_miscellaneous_1815975064
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Biochemistry
Biomedical and Life Sciences
Biomedical Engineering and Bioengineering
Biomedicine
Drug interactions
Drug Interactions - physiology
Drug Liberation - physiology
Drugs
Medical Law
Pharmaceutical Preparations - chemistry
Pharmaceutical Preparations - metabolism
Pharmaceuticals
Pharmacology/Toxicology
Pharmacy
Polymer industry
Polymers
Polymers - chemistry
Polymers - metabolism
Research Paper
Solubility
X-Ray Diffraction - methods
title Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T22%3A05%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Initial%20Drug%20Dissolution%20from%20Amorphous%20Solid%20Dispersions%20Controlled%20by%20Polymer%20Dissolution%20and%20Drug-Polymer%20Interaction&rft.jtitle=Pharmaceutical%20research&rft.au=Chen,%20Yuejie&rft.date=2016-10-01&rft.volume=33&rft.issue=10&rft.spage=2445&rft.epage=2458&rft.pages=2445-2458&rft.issn=0724-8741&rft.eissn=1573-904X&rft_id=info:doi/10.1007/s11095-016-1969-2&rft_dat=%3Cgale_proqu%3EA724212692%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1815310464&rft_id=info:pmid/27283830&rft_galeid=A724212692&rfr_iscdi=true